. Author manuscript; available in PMC: 2016 Jun 13.

Published in final edited form as: Prostate. 2015 Oct 23;76(3):286–293. doi: 10.1002/pros.23119

TABLE V.

Characteristics of Saracatinib RDT Patients Compared to Previously Studied Patients with mCRPC

Study	Median age (years)	≥75 years (average %)	Baseline PSA (μg/L)	Visceral disease (average %)
Saracatinib RDT	71	26	360	32
TAX 327^a	68	20	115	23
Cabazitaxel^b	68	19	136	25
Radium - 223^c	71	29	160	0

N Engl J Med 2004; 351:1,502–12.

Lancet 2010; 376:1,147–54.

N Engl J Med 2013; 369:213–23.

Averages were taken for the studies with two treatment arms.